renal cancer Archives

Novel treatment combination improves disease control in previously treated advanced renal cancer compared to standard of care

Published in The Lancet, results of the phase III LITESPARK-011 clinical trial point to the combination of belzutifan plus lenvatinib…

Belzutifan plus pembrolizumab post-surgery improves disease-free survival in patients with renal-cell carcinoma

Results from the international, randomized phase III LITESPARK-022 study show that the addition of hypoxia-inducible factor-2 alpha (HIF-2 α) inhibitor…

Immunotherapy-based combination of pembrolizumab plus lenvatinib as first-line treatment for patients with advanced non-clear cell renal cell carcinoma

Published in The Lancet Oncology (1) and co-authored by VHIO’s Cristina Suarez, results from the single-arm phase II KEYNOTE-B61 clinical…

CheckMate 9ER: extended follow-up data further supports nivolumab plus cabozantinib as first-line treatment of advanced renal cell carcinoma

The phase III international CheckMate 9ER trial continues to make headlines. Now published ahead of print in The Lancet Oncology…